[ET Net News Agency, 1 June 2021] Innovent Biologics, Inc. (01801) said the company and
AnHeart Therapeutics Co., Ltd. (AnHeart) have entered into an exclusive licence agreement
for the co-development and commercialization of AnHeart's lead drug candidate,
taletrectinib, an investigational next-generation tyrosine kinase inhibitor (TKI) designed
to effectively target ROS1 and NTRK in Greater China, including mainland China, Hong Kong,
Macau and Taiwan.
Under the terms of the agreement, the company will obtain exclusive rights to co-develop
and commercialize taletrectinib in Greater China. AnHeart will continue to be responsible
for the development of taletrectinib up to regulatory approval in mainland China and for
supplying taletrectinib for both developmental and commercial purposes in Greater China.
The company has the right to co-develop taletrectinib in Hong Kong, Macau and Taiwan up to
regulatory approval.
According to the agreement, AnHeart will receive upfront payment, R&D fees, and
potential milestone payments totalling USD189 million together with tiered royalties based
on annual net sales of taletrectinib in Greater China. (RC)